Peritoneal and Meningeal Relapse from Lung Adenocarcinoma After a Response to Gefitinib: A Case Report

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2014 Mar 21

PMID 24649247

Citations 1

Authors

Koichi Kurishima

Kunihiko Miyazaki

Tomohiro Tamura

Gen Ohara

Katsunori Kagohashi

Mio Kawaguchi

Hiroaki Satoh

Affiliations

Soon will be listed here.

Abstract

The prognosis of carcinomatous peritonitis and meningitis is poor since ascites and focal neurological dysfunctions usually do not improve despite the available treatment options for this devastating disease. This is a case report of peritoneal and meningeal relapse from lung adenocarcinoma following a response to gefitinib. A 72-year-old woman was diagnosed with adenocarcinoma in the upper lobe of the left lung, accompanied by a massive carcinomatous pleural effusion. Following a cisplati-based chemotherapy, gefitinib was initiated, achieving satisfactory disease control. At 8 months after gefitinib initiation, the patient developed abdominal distension, gait disturbance and visual disorder of the right eye. Adenocarcinoma cells were detected in the ascitic and pleural fluids. The findings of this case report suggest that clinicians should remain vigilant for this type of metastasis, although it is rarely encountered.

Citing Articles

EPAS1 promotes peritoneal carcinomatosis of non-small-cell lung cancer by enhancing mesothelial-mesenchymal transition.

Zhen Q, Zhang Y, Gao L, Wang R, Chu W, Zhao X Strahlenther Onkol. 2020; 197(2):141-149.

PMID: 32681351 DOI: 10.1007/s00066-020-01665-1.

References

Nakata H, Tuji T, Ohsaki Y . [A case of peritonitis carcinomatosa of pulmonary adenocarcinoma in which gefitinib was effective]. Gan To Kagaku Ryoho. 2004; 31(1):87-9. View

Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S . Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol. 2009; 4(11):1415-9. DOI: 10.1097/JTO.0b013e3181b62572. View

Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K . Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010; 5(7):950-5. DOI: 10.1097/JTO.0b013e3181e2138b. View

Satoh H, Ishikawa H, Yamashita Y, Kurishima K, Ohtsuka M, Sekizawa K . Peritoneal carcinomatosis in lung cancer patients. Oncol Rep. 2001; 8(6):1305-7. DOI: 10.3892/or.8.6.1305. View

Grossman S, Krabak M . Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999; 25(2):103-19. DOI: 10.1053/ctrv.1999.0119. View

Langer C, Soria J . The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2010; 11(2):82-90. DOI: 10.3816/CLC.2010.n.011. View

McNEILL P, Wagman L, Neifeld J . Small bowel metastases from primary carcinoma of the lung. Cancer. 1987; 59(8):1486-9. DOI: 10.1002/1097-0142(19870415)59:8<1486::aid-cncr2820590815>3.0.co;2-w. View

Omuro A, Kris M, Miller V, Franceschi E, Shah N, Milton D . High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005; 103(11):2344-8. DOI: 10.1002/cncr.21033. View

Ano S, Satoh H, Nakazawa K, Ohtsuka M, Anami Y, Noguchi M . Malignant meningitis secondary to lung adenocarcinoma: an unusual relapse. Intern Med. 2007; 46(20):1749-51. DOI: 10.2169/internalmedicine.46.0277. View

10.

Strik H, Prommel P . Diagnosis and individualized therapy of neoplastic meningitis. Expert Rev Anticancer Ther. 2010; 10(7):1137-48. DOI: 10.1586/era.10.86. View

11.

Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M . Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 2011; 67(6):1465-9. DOI: 10.1007/s00280-011-1555-6. View

12.

Yi H, Kim H, Kim Y, Han S, Oh D, Lee S . Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer. 2008; 65(1):80-4. DOI: 10.1016/j.lungcan.2008.10.016. View

13.

Warren S, GATES O . LUNG CANCER AND METASTASIS. Arch Pathol. 1964; 78:467-73. View

14.

Ruppert A, Beau-Faller M, Neuville A, Guerin E, Voegeli A, Mennecier B . EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J. 2009; 33(2):436-40. DOI: 10.1183/09031936.00162307. View

15.

Wasserstrom W, Glass J, Posner J . Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982; 49(4):759-72. DOI: 10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7. View

16.

ABRAMS H, Spiro R, Goldstein N . Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950; 3(1):74-85. DOI: 10.1002/1097-0142(1950)3:1<74::aid-cncr2820030111>3.0.co;2-7. View

17.

Jimenez Mateos A, Cabrera Naranjo F, Gonzalez Hernandez A, Fabre Pi O, Diaz Nicolas S, Lopez Fernandez J . Neoplastic meningitis.Review of a clinical series. Neurologia. 2010; 26(4):227-32. DOI: 10.1016/j.nrl.2010.07.020. View

18.

Kim M, Lee K, Lee J, Choi J, Hyun M . Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer. 2005; 50(2):265-9. DOI: 10.1016/j.lungcan.2005.05.022. View

19.

Su H, Tsai C, Perng R . Peritoneal carcinomatosis in lung cancer. Respirology. 2008; 13(3):465-7. DOI: 10.1111/j.1440-1843.2008.01268.x. View